Skip to search formSkip to main contentSkip to account menu

insulin degludec

Known as: (1A-21A),(1B-29B)-insulin (human), 29B-(N6-(N-(15-carboxy-1- oxopentadecyl)-L-gamma- glutamyl)-L-lysine)-, INSULIN,DEGLUDEC,HUMAN/RDNA, degludec 
National Institutes of Health

Related topics

Related topics

13 relations
3 ML insulin degludec 200 UNT/ML Pen Injector3 ML insulin degludec 200 UNT/ML Pen Injector [Tresiba]Decreased Lipolysis [PE]Diabetes Mellitus, Insulin-Dependent

Broader (1)

Insulin, Long-Acting

Narrower (1)

Xultophy

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Efficacy and Safety of Degludec Compared to Glargine 300 Units/mL in Insulin-Experienced Patients With Type 2 Diabetes: Trial Protocol Amendment (NCT03078478)
Background: A head-to-head trial (NCT03078478) between insulin degludec and insulin glargine U300 with the primary objective of… 
2018
2018
Reduction in insulin degludec dosing for multiple exercise sessions improves time spent in euglycaemia in people with type 1 diabetes: A randomized crossover trial
To compare the time spent in specified glycaemic ranges in people with type 1 diabetes (T1D) during 5 consecutive days of… 
2016
2016
A 1‐year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal–bolus insulin therapy…
The aim of the present prospective observational study was to assess long‐term efficacy and safety of insulin degludec as a part… 
Review
2015
Review
2015
Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice—a case-based evaluation
Abstract Background: Clinical experience of patients is an additional source of information that can inform prescribing decisions… 
2013
2013
Insulin degludec improves health-related quality of life (SF-36®) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials
To compare the effect of insulin degludec and insulin glargine on health‐related quality of life in patients with Type 2 diabetes… 
Review
2013
Review
2013
Flexibly timed once‐daily dosing with degludec: a new ultra‐long‐acting basal insulin
Insulin treatment in type 1 and type 2 diabetes (T1D and T2D) is highly efficacious, but in practice, non‐adherence and… 
2012
2012
Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile compared with insulin glargine
Insulin degludec (IDeg) is an ultra-long-acting basal insulin that forms soluble multi-hexamers after injection. These release… 
1997
1997
Gamma interferon prevents diabetes in the BB rat
The BB rat model of human insulin-dependent diabetes mellitus (IDDM) spontaneously develops diabetes through an autoimmune… 
1995
1995
Characterization of Fc gamma receptors on rat mucosal mast cells using a mutant Fc epsilon RI-deficient rat basophilic leukemia line.
A novel rat basophilic leukemia (RBL) 2H3 subline of rat mucosal mast cells deficient in the expression of the gamma chain (RBL… 
1988
1988
Identification of base substitutions in the promoter regions of the A gamma- and G gamma-globin genes in A gamma- (or G gamma-) beta+-HPFH heterozygotes using the DNA-amplification-synthetic…
DNA amplification combined with hybridization with 32P-labeled synthetic oligonucleotide probes has been used to identify base… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)